BRAF and colorectal carcinoma: In a retrospective study by Kopetz et al., BRAF-mutated CRC patients with the consensus molecular subtype (CMS-4) and BRAF mutant (BM1) subtypes had better responses to triplet therapy as compared to doublet therapy.